Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Menopausal female patients aged 65 years and older~* Patients with severe nocturia, defined as waking to void 3 or more times at night due to an urge to void~* Patients capable of understanding and having signed the consent form after full discussion of the research, nature of the treatment, its risks and benefits~Exclusion Criteria:~* Urinary tract infection or chronic inflammation such as interstitial cystitis and bladder stones~* Urinary and gastric retention~* Narrow-angle glaucoma~* von Willebrand's disease~* Chronic severe constipation or history of gastrointestinal obstructive disease~* Untreated congestive heart failure and venous insufficiency~* Untreated hypertension or tachycardia~* Untreated renal or liver disease~* Untreated diabetes mellitus or insipidus~* Unexplained and untreated electrolyte disturbances~* Any clinical condition which in the opinion of the investigator would not allow safe completion of the study~* Current use of diuretics with untreated electrolyte disturbances~* Patients taking drugs known to be strong CYP3A4 inhibitors (protease inhibitors, ketoconazole, clarithromycin) or strong CYP3A4 inducers (carbamazepine, phenytoin, St. John's Wort) used on a regular basis~* Patients taking anticholinergic or antispasmodic medications who did not comply with a minimum 14 days washout period~* Previous failed therapy with Fesoterodine or Desmopressin~* Hypersensitivity or intolerance to Fesoterodine or Desmopressin~* Hypersensitivity to soya, peanuts or lactose~* Clinically significant outlet obstruction as determined by the investigator~* Patients with Post Void Residual (PVR) \> 100 ml~* Patients with Mini-Mental State Exam (MMSE) \<24

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desmopressin (Type: ACTIVE_COMPARATOR): Patients randomized to receive Desmopressin will be given 0.1mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 0.2mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
- Fesoterodine (Type: ACTIVE_COMPARATOR): Patients randomized to receive Fesoterodine will be given 4mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 8mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).